A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence

Autor:	Rebecca McKetin, James Shearer, Tim Slade, Craig Rodgers, John Lewis, Ingrid van Beek, Shane Darke, Donna Brady, Richard P. Mattick, A. Wodak
Rok vydání:	2009
Předmět:	Adult Male media_common.quotation_subject Amphetamine-Related Disorders Placebo-controlled study Medicine (miscellaneous) Modafinil Placebo Severity of Illness Index Cocaine dependence law.invention Young Adult Double-Blind Method Randomized controlled trial Recurrence law medicine Humans Benzhydryl Compounds Adverse effect media_common Substance dependence Australia Middle Aged Abstinence medicine.disease Substance Abuse Detection Psychiatry and Mental health Treatment Outcome Anesthesia Central Nervous System Stimulants Female Psychology medicine.drug
Zdroj:	Addiction. 104:224-233
ISSN:	1360-0443 0965-2140
Popis:	Aim To examine the safety and efficacy of modafinil (200 mg/day) compared to placebo in the treatment of methamphetamine dependence and to examine predictors of post-treatment outcome. Participants and design Eighty methamphetamine-dependent subjects in Sydney, Australia were allocated randomly to modafinil (200 mg/day) (n = 38) or placebo (n = 42) under double-blind conditions for 10 weeks with a further 12 weeks post- treatment follow-up. Measures Comprehensive drug use data (urine specimens and self-report) and other health and psychosocial data were collected weekly during treatment and research interviews at baseline, week 10 and week 22. Results Treatment retention and medication adherence were equivalent between groups. There were no differences in methamphetamine abstinence, craving or severity of dependence. Medication-compliant subjects tended to provide more methamphetamine-negative urine samples over the 10-week treatment period (P = 0.07). Outcomes were better for methamphetamine-dependent subjects with no other substance dependence and those who accessed counselling. There were statistically significant reductions in systolic blood pressure (P = 0.03) and weight gain (P = 0.05) in modafinil-compliant subjects compared to placebo. There were no medication-related serious adverse events. Adverse events were generally mild and consistent with known pharmacological effects. Conclusions Modafinil demonstrated promise in reducing methamphetamine use in selected methamphetamine-dependent patients. The study findings support definitive trials of modafinil in larger multi-site trials.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6adc78fcdcdef5422d5f361318306bc6 https://doi.org/10.1111/j.1360-0443.2008.02437.x Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.